vonicog alfa

This medicine is authorised for use in the European Union.


Veyvondi is a medicine used to control bleeding in patients with von Willebrand disease (an inherited bleeding disorder), who cannot be treated with another medicine called desmopressin or when desmopressin is ineffective.

It is used ‘on demand’ to treat bleeding episodes and is also used to prevent and treat bleeding during surgery. Veyvondi contains the active substance vonicog alfa.

This EPAR was last updated on 19/09/2023

Authorisation details

Product details
Agency product number
Active substance
vonicog alfa
International non-proprietary name (INN) or common name
vonicog alfa
Therapeutic area (MeSH)
von Willebrand Diseases
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Baxalta Innovations GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Industriestrasse 67
A-1221 Vienna

Product information

31/08/2023 Veyvondi - EMEA/H/C/004454 - II/0031

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Veyvondi is indicated in adults (age 18 and older) with von Willebrand Disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or not indicated for the
- Treatment of haemorrhage and surgical bleeding
- Prevention of surgical bleeding.

Veyvondi should not be used in the treatment of Haemophilia A.

Assessment history

Related content

How useful was this page?

Add your rating
2 ratings
4 ratings